Open Versus Arthroscopic Stabilization of Shoulder Instability with Subcritical Bone Loss: the OASIS Trial
Launched by UNIVERSITY OF PITTSBURGH · Mar 17, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The OASIS Trial is studying different surgical methods to treat shoulder instability, particularly for people who have experienced a traumatic shoulder dislocation and have some bone loss in their shoulder joint. The goal is to find out which surgery helps patients recover the fastest so they can return to their jobs, sports, or military duties, while also improving their shoulder function. This trial is open to military personnel and civilians aged 17 to 50 who have had a recent shoulder dislocation and have a specific amount of bone loss that can be measured through a CT scan.
Participants in the trial will undergo one of three surgical procedures and will follow a post-operative rehabilitation program. To be eligible, individuals must have experienced a recent shoulder dislocation with 10-20% bone loss in the shoulder joint but should not have any other chronic shoulder issues, significant prior injuries, or conditions that might affect their recovery. Those who join the trial can expect close monitoring and support as they work towards regaining full function in their shoulder.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Civilians and military personnel ages 17 to 50
- • Traumatic anterior shoulder dislocation
- • Associated subcritical bone loss between 10-20% less the glenoid width quantified by standard of care CT scan
- Exclusion Criteria:
- • Chronic, non-traumatic multi-directional instability based on clinical exam.
- • Concurrent shoulder injury (e.g. rotator cuff tears, motor nerve pathologies, osteoarthritis of a Samilson-Prieto grade \>2).
- • Prior instability or rotator cuff procedure on involved shoulder (including intra-articular soft tissue surgery).
- • Humeral sided bone lesion (Hill-Sachs lesion) that is sufficiently large enough to render the lesion "off-track" even after a bony augmentation procedure would be performed.
- • Neuromuscular and other movement control pathologies including seizures.
- • Vascular injury associated with the shoulder trauma.
- • Traumatic brain injury or any condition that would preclude the ability to comply with post-operative guidelines.
- • Does not plan to return to pre-injury levels of work, sports or military duty.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Pittsburgh, Pennsylvania, United States
Farmington, Connecticut, United States
Durham, North Carolina, United States
Chapel Hill, North Carolina, United States
San Diego, California, United States
Chapel Hill, North Carolina, United States
Fort Sam Houston, Texas, United States
Fort Carson, Colorado, United States
Charlottesville, Virginia, United States
Nashville, Tennessee, United States
Camp Lejeune, North Carolina, United States
Bethesda, Maryland, United States
Vail, Colorado, United States
Annapolis, Maryland, United States
Providence, Rhode Island, United States
Tempe, Arizona, United States
Columbus, Ohio, United States
Providence, Rhode Island, United States
Patients applied
Trial Officials
Adam Popchak, PhD, PT
Principal Investigator
University of Pittsburgh
Jonathan Dickens, MD
Principal Investigator
Duke University
James J Irrgang, PhD, PT, ATC
Study Chair
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials